Pharmaceutical News

RSS

Global drug distribution programs one factor in hastening drug resistance, report says

A Center for Global Development (CGD) report released Tuesday details factors leading to increased drug resistance worldwide, including drug distribution programs in developing countries, Reuters reports.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as "I5NP") for the prophylaxis of delayed graft function in kidney transplant patients.

16 Jun 2010

Topical NSAIDs are safe and effective for acute pain: Researchers

Gels, creams and sprays containing painkillers such as ibuprofen, diclofenac, ketoprofen, and piroxicam are safe and effective treatments for local pain, according to Cochrane Researchers. A new systematic review they have conducted shows that topical non-steroidal anti-inflammatory drugs are more effective than placebos for treating short-term pain and have few side effects.

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

Hemispherx Biopharma, Inc., announced that the Company executed an exclusive revenue sharing Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA.

16 Jun 2010

FDA cautions on infant overdose risk with liquid Vitamin D

The Food and Drug Administration today alerted parents and caregivers that some liquid Vitamin D supplement products are sold with droppers that could allow excessive dosing of Vitamin D to infants.

16 Jun 2010

AIDS activists to protest BMS' Reyataz pricing, policies at Goldman Sachs Global Healthcare Conference

“All of AHF's efforts, including this protest, are designed to let people know that BMS is causing great harm to people with HIV/AIDS with its unwarranted pricing of Reyataz”

15 Jun 2010

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Raptor Pharmaceutical Corp., announced that the European Medicines Agency's ("EMA") Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion recommending orphan medicinal product designation for DR Cysteamine for the potential treatment of cystinosis.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Tips for correct application of sunscreen

You've gotten the message about the importance of sun protection, you're stocked up on sunscreen that's at least 15 SPF, and you're diligent about putting it on before you head outside. Once you've gotten this far, there's no reason to risk sunburns by applying it incorrectly. But, all too often, that's exactly what happens, says a Saint Louis University dermatologist.

15 Jun 2010

Comprehensive source for treatment information of atrial fibrillation in the European market

Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.

15 Jun 2010

ATA members raise concern about reduction in dietary iodine intake

Following publication of an article in the February 18 issue of the New England Journal of Medicine (Vol. 362 No. 7 pp 590-599) by Bibbins-Domingo, et al. that projected the effect of moderate dietary salt reductions on future cardiac disease rates, several members of the American Thyroid Association, concerned about the subsequent potential reduction in availability of iodine, have responded with a letter in the current issue of the NEJM (Vol. 362 No. 23 pp 2224-2226).

15 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Cheap drug that prevents bleeding may save 100,000 lives each year: Study

Researchers have shown that a cheap and easy to use drug that stops bleeding may save up to 100,000 lives each year from injuries associated with road accidents and violence. The study was published this Tuesday in the acclaimed international journal The Lancet and was conducted by doctors at the London School of Hygiene and Tropical Medicine.

14 Jun 2010

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

NPR continues its examination of medical marijuana: "Fourteen states and the District of Columbia have launched a medical experiment that doesn't follow any of the rules of science. By approving the use of marijuana as a medicine — with varying kinds of restrictions — these jurisdictions are bypassing the federal government's elaborate processes for approving medicines."

14 Jun 2010

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

14 Jun 2010

Pharmaceutical News

Global drug distribution programs one factor in hastening drug resistance, report says

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Topical NSAIDs are safe and effective for acute pain: Researchers

New combination appears to be effective against cancer stem cells in pancreatic cancer

ARBs may be linked with increased risk of developing cancer: US scientists

Hemispherx announces exclusive revenue sharing agreement with GP Pharm

FDA cautions on infant overdose risk with liquid Vitamin D

AIDS activists to protest BMS' Reyataz pricing, policies at Goldman Sachs Global Healthcare Conference

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Tips for correct application of sunscreen

Comprehensive source for treatment information of atrial fibrillation in the European market

ATA members raise concern about reduction in dietary iodine intake

Sulindac shuts down cancer cell growth, initiates cell death: Study

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Cheap drug that prevents bleeding may save 100,000 lives each year: Study

UCB announces availability of Vimpat oral solution formulation

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News